Epigral Limited has informed the Exchange about Investor Presentation
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Epigral reported its highest-ever annual revenue of ₹2,565 Cr in FY25, up 33% YoY, driven by 11% volume growth led by Derivatives & Specialty chemicals. EBITDA jumped 48% to ₹711 Cr with margin expanding to 28% (from 25%), and PAT surged 82% to ₹357 Cr. ROCE improved to 25% and Net Debt/EBITDA fell sharply to 0.7x from 2.0x, leading to a credit rating upgrade to CRISIL AA. The board approved doubling of CPVC Resin and Epichlorohydrin capacities at a capex of ~₹780 Cr, expected by H1 FY27. The company raised ₹333 Cr via QIP and declared a total dividend of ₹6 per share (60% on face value). Derivatives & Specialty now contribute 54% of revenue, up from 45%, with a target of ~70% by FY28E.
Strong results with margin expansion, deleveraging, and a credit rating upgrade signal improving fundamentals. The announced capex of ~₹780 Cr for CPVC and ECH expansion supports future growth, but will increase near-term spending. Overall positive for shareholders, with higher dividend and clear roadmap toward higher-margin specialty chemicals.